2Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology, 2007, 45: 1056-1075.
3Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5: 890-897.
4Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46: 254-265.
5Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology, 2008, 134: 405-415.
6Lok AS. I-IBV treatment in dications and efficacy of approved nucleoside/nucleotide inhibitors//EASL-AASLD-APASL-ALEH-IASL Conference: hepatitis B and C virus resistance to antiviral therapies, Pads, 2008. http://www.easl.ch/hepatitis-conference.
4Zeng M,Mao Y,Yao G,et al.A double-blind randomized trial ofadefovir dipivoxil in Chinese subjects with HBeAg-positivechronic hepatitis B[J].Hepatology,2006,44(1):108-116.
5Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Long-termtherapy with adefovir dipivoxil for HBeAg-negative chronichepatitis B[J].N Engl J Med,2005,325(26):2673-2681.
6European Association for the study of the Live. EASL cl- inical practice guidelines: management of chronic hepati- tis B virus infection [J]. J Hepatol , 2012,57 ( 1 ) : 167.
8Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with ente- cavir in patients with impaired liver function[J]. Hepatolo- gy, 2009,50(6):2 001.
